“Acute Bacterial Skin and Skin-Structure Infection Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Bacterial Skin and Skin-Structure Infection Market.

The Acute Bacterial Skin and Skin-Structure Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the ABSSSI Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Bacterial Skin and Skin-Structure Infection treatment therapies with a considerable amount of success over the years. 

• Acute Bacterial Skin and Skin-Structure Infection companies working in the treatment market are Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others, are developing therapies for the Acute Bacterial Skin and Skin-Structure Infection treatment 

• Emerging Acute Bacterial Skin and Skin-Structure Infection therapies in the different phases of clinical trials are- Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others are expected to have a significant impact on the Acute Bacterial Skin and Skin-Structure Infection market in the coming years. 

• In June 2024, Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), a company focused on developing a new class of synthetic anti-infectives, announced it has received approval from the Human Research Ethics Committee (HREC) to begin a Phase II trial. This trial will evaluate their lead candidate, RECCE® 327 (R327), as a topical broad-spectrum gel for treating acute bacterial skin and skin structure infections (ABSSSI).

• In April 2024, The FDA has approved Basilea’s Zevtera (ceftobiprole) for treating three types of infections. This approval benefits patients who have developed resistance to the existing antibiotics in the U.S., many of which have been available for decades. Zevtera is now approved for use in adults with acute bacterial skin and skin structure infections (ABSSSI) and staphylococcus aureus bacteremia (SAB), a potentially fatal bloodstream infection. Additionally, it can be administered to patients aged 3 months and older to treat community-acquired bacterial pneumonia (CABP).

ABSSSI Overview

ABSSSI stands for Acute Bacterial Skin and Skin Structure Infection. This term refers to a range of bacterial infections that affect the skin and the underlying soft tissues. 

Get a Free Sample PDF Report to know more about Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-pipeline-insight

Emerging Acute Bacterial Skin and Skin-Structure Infection Drugs Under Different Phases of Clinical Development Include:

• Contezolid acefosamil: MicuRx

• Zevtera: Basilea Pharmaceuticals

• Iclaprim: Motif Bio

• Levonadifloxacin: Wockhardt

• Dalbavancin: Allergan

• ceftobiprole medocaril: Basilea Pharmaceutical

• Tedizolid phosphate: Merck Sharp & Dohme LLC

• linezolid: Arrevus Inc.

• Oritavancin: The Medicines Company

• NXL103: Novexel Inc

• Daptomycin: PolyMedix, Inc.

• Xydalba: Hippocrates Research

• Kimyrsa: Melinta Therapeutics, Inc.

ABSSSI Route of Administration

Acute Bacterial Skin and Skin-Structure Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

ABSSSI Molecule Type

Acute Bacterial Skin and Skin-Structure Infection Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutics Assessment

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Product Type

• Acute Bacterial Skin and Skin-Structure Infection By Stage and Product Type

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Route of Administration

• Acute Bacterial Skin and Skin-Structure Infection By Stage and Route of Administration

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Molecule Type

• Acute Bacterial Skin and Skin-Structure Infection by Stage and Molecule Type

DelveInsight’s ABSSSI Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Acute Bacterial Skin and Skin-Structure Infection product details are provided in the report. Download the Acute Bacterial Skin and Skin-Structure Infection pipeline report to learn more about the emerging Acute Bacterial Skin and Skin-Structure Infection therapies

Some of the key companies in the ABSSSI Therapeutics Market include:

Key companies developing therapies for Acute Bacterial Skin and Skin-Structure Infection are – Merck & Co. Inc., Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Cipher Pharmaceuticals, Paratek Pharmaceuticals Inc., Melinta Therapeutics, Inc., Allergan PLC, Menarini Group, Sandoz Inc. (Novartis), Glenmark Pharmaceuticals Ltd, Pfizer Inc., and others.

Acute Bacterial Skin and Skin-Structure Infection Pipeline Analysis:

The Acute Bacterial Skin and Skin-Structure Infection pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Bacterial Skin and Skin-Structure Infection with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Bacterial Skin and Skin-Structure Infection Treatment.

• Acute Bacterial Skin and Skin-Structure Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acute Bacterial Skin and Skin-Structure Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Bacterial Skin and Skin-Structure Infection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Bacterial Skin and Skin-Structure Infection drugs and therapies

Acute Bacterial Skin and Skin-Structure Infection Pipeline Market Drivers

• Increasing Prevalence, Advanced Diagnostics, Innovative Therapies, R&D Investments, Regulatory Support, Public Awareness, Technological Advancements, are some of the important factors that are fueling the Acute Bacterial Skin and Skin-Structure Infection Market.

Acute Bacterial Skin and Skin-Structure Infection Pipeline Market Barriers

• However, Antibiotic Resistance, High R&D Costs, Regulatory Hurdles, Market Competition, Adverse Side Effects, Insurance and Reimbursement Issues, and other factors are creating obstacles in the Acute Bacterial Skin and Skin-Structure Infection Market growth.

Scope of Acute Bacterial Skin and Skin-Structure Infection Pipeline Drug Insight    

• Coverage: Global

• Key Acute Bacterial Skin and Skin-Structure Infection Companies: Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others

• Key Acute Bacterial Skin and Skin-Structure Infection Therapies: Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others

• Acute Bacterial Skin and Skin-Structure Infection Therapeutic Assessment: Acute Bacterial Skin and Skin-Structure Infection current marketed and Acute Bacterial Skin and Skin-Structure Infection emerging therapies

• Acute Bacterial Skin and Skin-Structure Infection Market Dynamics: Acute Bacterial Skin and Skin-Structure Infection market drivers and Acute Bacterial Skin and Skin-Structure Infection market barriers 

Request for Sample PDF Report for Acute Bacterial Skin and Skin-Structure Infection Pipeline Assessment and clinical trials

Table of Contents

1. Acute Bacterial Skin and Skin-Structure Infection Report Introduction

2. Acute Bacterial Skin and Skin-Structure Infection Executive Summary

3. Acute Bacterial Skin and Skin-Structure Infection Overview

4. Acute Bacterial Skin and Skin-Structure Infection- Analytical Perspective In-depth Commercial Assessment

5. Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutics

6. Acute Bacterial Skin and Skin-Structure Infection Late Stage Products (Phase II/III)

7. Acute Bacterial Skin and Skin-Structure Infection Mid Stage Products (Phase II)

8. Acute Bacterial Skin and Skin-Structure Infection Early Stage Products (Phase I)

9. Acute Bacterial Skin and Skin-Structure Infection Preclinical Stage Products

10. Acute Bacterial Skin and Skin-Structure Infection Therapeutics Assessment

11. Acute Bacterial Skin and Skin-Structure Infection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Bacterial Skin and Skin-Structure Infection Key Companies

14. Acute Bacterial Skin and Skin-Structure Infection Key Products

15. Acute Bacterial Skin and Skin-Structure Infection Unmet Needs

16 . Acute Bacterial Skin and Skin-Structure Infection Market Drivers and Barriers

17. Acute Bacterial Skin and Skin-Structure Infection Future Perspectives and Conclusion

18. Acute Bacterial Skin and Skin-Structure Infection Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services